Resmetirom
MASH with moderate to advanced fibrosis (F2-F3)
Key Facts
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing novel therapeutics for MASH, formerly known as NASH. The company has successfully brought the first FDA-approved treatment for MASH to market in the U.S. and EU, marking a historic milestone in liver disease treatment. Madrigal's innovative THR-β agonist platform addresses the underlying causes of liver fibrosis and metabolic dysfunction, with multiple Phase 3 trials ongoing to expand treatment options for MASH patients.
View full company profileAbout Madrigal Pharmaceuticals
Madrigal Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing novel therapeutics for MASH, formerly known as NASH. The company has successfully brought the first FDA-approved treatment for MASH to market in the U.S. and EU, marking a historic milestone in liver disease treatment. Madrigal's innovative THR-β agonist platform addresses the underlying causes of liver fibrosis and metabolic dysfunction, with multiple Phase 3 trials ongoing to expand treatment options for MASH patients.
View full company profileAbout Madrigal Pharmaceuticals
Madrigal Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing novel therapeutics for MASH, formerly known as NASH. The company has successfully brought the first FDA-approved treatment for MASH to market in the U.S. and EU, marking a historic milestone in liver disease treatment. Madrigal's innovative THR-β agonist platform addresses the underlying causes of liver fibrosis and metabolic dysfunction, with multiple Phase 3 trials ongoing to expand treatment options for MASH patients.
View full company profile